Global life sciences company, Cytiva, is creating solutions to the challenges of viral vector-based gene therapies with its new ELEVECTA cell lines.

According to Emmanuel Abate, President Genomic Medicine, Cytiva: “To make gene therapy a realistic option for more patients, we need to be able to standardize its manufacturing. We’ve gone to the heart of the process by creating viral vector cell lines that will make a big impact to developers of gene therapies.”

Tapping into its deep expertise, the company has created three cell lines for adeno-associated virus (AAV) production. Together, the three lines comprehensively meet the distinct objectives of various therapeutic programs with the ability to transition between cell lines as needs evolve, and they can be paired with Cytiva’s established cell culture media offering:

  • A transient cell line that provides speed and flexibility enabling researchers to easily integrate it into their existing workflow. This cell line is paired with a new cell culture medium, HyClone prime expression designed to enhance performance. Both the cell line and corresponding media will be available soon.
  • A packaging cell line that eases the screening of genes of interest while enabling efficiencies across clinical stages and assets. This line is available now in selected formulations.
  • A producer cell line that stably integrates all four required genes for AAV production. Production starts by simply adding an induction agent—no transfection is needed. This line is available now to be customized to each individual therapy.


“We now offer end-to-end solutions for viral vector manufacturing,” says Abate. “With our new cell line offering, our customers can deliver higher quality treatments and significantly improve patient access today as well as meet the increasing demand for viral vector material tomorrow.”

Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Future Of Gamma Delta T Cell Therapies

Gamma delta T cell-based immunotherapies have emerged as a promising frontier in cancer treatment and beyond, building on the success of chimeric antigen receptor T-cell (CAR T cell) therapy and expanding on the potential of the immune system as a therapeutic...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.